“Pivot’s industry leading product pipeline and Intellectual Property portfolio continues to attract attention from several groups, particularly in the food and beverage, nutraceutical and pharmaceutical industries,” said Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals. “We are evaluating multiple opportunities that will generate significant value for both our company and shareholders while our product team remains focused on developing and expanding our technology portfolio to ensure that we remain ahead of the curve when it comes to product formulation and development.”
Dr. Frankham continued, “As a business, we see a glaring demand for differentiated products and solutions, backed by proven technologies, that match the vast needs of medicinal and recreational consumers outside of the dried flower segment. We will capitalize on this segment of the market and we are working towards building a sustainable, long-term business with the ultimate goal of delivering value to the consumer and shareholders. Our suite of products remain on track for commercialization in 2018 and beyond. I assure our shareholders that we are working diligently and proactively to create value and restore confidence in Pivot Pharmaceuticals.”
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has licensed or acquired “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. Pivot continues to expand its Intellectual Property portfolio. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc. or Pivot Green Stream Health Solutions Inc., or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
SOURCE Pivot Pharmaceuticals Inc.
View original content: http://www.newswire.ca/en/releases/archive/May2018/15/c1623.html
Pivot Pharmaceuticals Inc., Patrick Frankham, PhD, MBA, Chief Executive Officer, Email: [email protected]; Investor Relations, Virtus Advisory Group, Email: [email protected], Tel: 416-644-5081Copyright CNW Group 2018